GKB (1707) reported revenue of NT$748.3 million for Oct 2026, -30.8% year on year and +3.0% from the previous month. Revenue for Jan–Oct 2026 was NT$7.59 billion (-8.9% year on year).
In Oct 2026, it ranked No. 9 by revenue among 160 Biotech & Medical companies.
Next ex-date: 2026-12-30 (Cash dividend, cash per share NT$1.9) Taiwan ex-dividend calendar →
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$748.3 million | -30.8% | +3.0% |
| Sep 2026 | NT$726.3 million | -7.9% | +2.9% |
| Aug 2026 | NT$706.1 million | -20.1% | -1.5% |
| Jul 2026 | NT$716.7 million | -5.1% | -12.6% |
| Jun 2026 | NT$819.6 million | -7.2% | +4.1% |
| May 2026 | NT$787.6 million | -4.8% | -2.3% |
| Apr 2026 | NT$806.4 million | -6.0% | -6.0% |
| Mar 2026 | NT$857.7 million | -7.0% | +37.1% |
| Feb 2026 | NT$625.8 million | -1.3% | -21.2% |
| Jan 2026 | NT$794.5 million | +14.1% | -4.2% |
| Dec 2025 | NT$829.4 million | -30.4% | -24.1% |
| Nov 2025 | NT$1.09 billion | +0.8% | +1.0% |
| Oct 2025 | NT$1.08 billion | +22.9% | +37.0% |
| Sep 2025 | NT$788.7 million | -36.0% | -10.8% |
| Aug 2025 | NT$884.1 million | +5.4% | +17.1% |
| Jul 2025 | NT$755 million | -8.8% | -14.6% |
| Jun 2025 | NT$883.6 million | +0.0% | +6.8% |
| May 2025 | NT$827.4 million | -13.0% | -3.6% |
| Apr 2025 | NT$858 million | -7.2% | -6.9% |
| Mar 2025 | NT$921.8 million | -3.9% | +45.3% |
| Feb 2025 | NT$634.3 million | +6.0% | -8.9% |
| Jan 2025 | NT$696.1 million | -11.8% | -41.6% |
| Dec 2024 | NT$1.19 billion | -0.5% | +10.0% |
| Nov 2024 | NT$1.08 billion | -8.3% | +23.3% |
| Oct 2024 | NT$879.1 million | +7.0% | -28.7% |
Jan–Oct 2026 cumulative: NT$7.59 billion (-8.9% YoY)
Other Biotech & Medical companies
Compare with peers: GKB vs PEC / GKB vs Lotus Pharm / GKB vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16